导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.75% | 1733/4407 |
| 近一周 | -1.19% | 2058/5016 |
| 近一月 | -3.12% | 1055/4972 |
| 近一季 | -4.89% | 1584/4811 |
| 近半年 | -3.66% | 2530/4547 |
| 近一年 | 4.20% | 1581/4077 |
| 近两年 | 29.14% | 2130/2754 |
| 近三年 | 17.57% | 1432/2082 |
| 成立以来 | 61.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.31% 1576/4961 |
7.49% 2699/5312 |
- - |
- - |
| 2025 | 5.84% 2984/4813 |
-4.83% 3228/3635 |
1.11% 2459/4076 |
9.91% 3329/4524 |
0.07% 2240/4813 |
| 2024 | 15.23% 951/3463 |
4.90% 420/2808 |
2.11% 397/3014 |
8.11% 2771/3129 |
-0.50% 1443/3463 |
| 2023 | 2.11% 334/2656 |
12.33% 299/2280 |
-0.42% 384/2385 |
-4.58% 1171/2515 |
-4.33% 965/2655 |
| 2022 | -14.64% 382/2207 |
-11.85% 549/1919 |
3.18% 1199/2016 |
-9.54% 287/2113 |
3.75% 649/2208 |
| 2021 | 16.41% 267/1822 |
-0.17% 337/1255 |
4.68% 858/1330 |
9.08% 145/1466 |
2.12% 694/1822 |
| 2020 | 14.84% 788/1250 |
-9.99% 737/1028 |
4.45% 906/1067 |
9.09% 675/1164 |
11.97% 507/1184 |
| 2019 | 5.92% 745/1092 |
12.60% 705/754 |
-7.04% 540/804 |
-1.36% 650/850 |
2.59% 862/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时央调ETF联接A VS. 长安沪深300非周期A(740101) |